Switch theme
Sign up to access all valuation multiples
Medeze Group PCL is engaged in the business of providing stem cell storage, analyzing, isolation, cultivation and preservation services for medical use. It is organised into four reportable segments: Stem cell sample collection service segment; White blood cell potential testing service segment; Other services segment and Sales of products segment.
2010
n/a
LTM Revenue $26.4M
LTM EBITDA $12.7M
$137M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Medeze Group has a last 12-month revenue of $26.4M and a last 12-month EBITDA of $12.7M.
In the most recent fiscal year, Medeze Group achieved revenue of $24.4M and an EBITDA of $12.1M.
Medeze Group expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Medeze Group valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $20.6M | $24.4M | XXX | XXX | XXX |
| Gross Profit | n/a | $16.2M | XXX | XXX | XXX |
| Gross Margin | NaN% | 66% | XXX | XXX | XXX |
| EBITDA | $9.8M | $12.1M | XXX | XXX | XXX |
| EBITDA Margin | 47% | 50% | XXX | XXX | XXX |
| Net Profit | n/a | $7.0M | XXX | XXX | XXX |
| Net Margin | NaN% | 29% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Medeze Group's stock price is THB 6 (or $0).
Medeze Group has current market cap of THB 6.7B (or $198M), and EV of THB 4.6B (or $137M).
See Medeze Group trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $137M | $198M | XXX | XXX | XXX | XXX | $0.01 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Medeze Group has market cap of $198M and EV of $137M.
Medeze Group's trades at 5.2x LTM EV/Revenue multiple, and 10.8x LTM EBITDA.
Analysts estimate Medeze Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Medeze Group and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $137M | XXX | XXX | XXX |
| EV/Revenue | 5.6x | XXX | XXX | XXX |
| EV/EBITDA | 11.3x | XXX | XXX | XXX |
| P/E | 19.9x | XXX | XXX | XXX |
| P/E/Growth | 0.6x | XXX | XXX | XXX |
| EV/FCF | 142.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpMedeze Group's NTM/LTM revenue growth is 26%
Medeze Group's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Medeze Group's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Medeze Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Medeze Group and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 18% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 50% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 24% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 76% | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 18% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 20% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 2% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 34% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Lineage Cell Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Arovella Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Aroa Biosurgery | XXX | XXX | XXX | XXX | XXX | XXX |
| Cynata Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Mesoblast | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Medeze Group acquired XXX companies to date.
Last acquisition by Medeze Group was XXXXXXXX, XXXXX XXXXX XXXXXX . Medeze Group acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Medeze Group founded? | Medeze Group was founded in 2010. |
| Where is Medeze Group headquartered? | Medeze Group is headquartered in Thailand. |
| Is Medeze Group publicy listed? | Yes, Medeze Group is a public company listed on BKK. |
| What is the stock symbol of Medeze Group? | Medeze Group trades under MEDEZE ticker. |
| When did Medeze Group go public? | Medeze Group went public in 2024. |
| Who are competitors of Medeze Group? | Similar companies to Medeze Group include e.g. Lineage Cell Therapeutics, Arovella Therapeutics, Aroa Biosurgery, Cynata Therapeutics. |
| What is the current market cap of Medeze Group? | Medeze Group's current market cap is $198M |
| What is the current revenue of Medeze Group? | Medeze Group's last 12-month revenue is $26.4M. |
| What is the current EBITDA of Medeze Group? | Medeze Group's last 12-month EBITDA is $12.7M. |
| What is the current EV/Revenue multiple of Medeze Group? | Current revenue multiple of Medeze Group is 5.2x. |
| What is the current EV/EBITDA multiple of Medeze Group? | Current EBITDA multiple of Medeze Group is 10.8x. |
| What is the current revenue growth of Medeze Group? | Medeze Group revenue growth between 2023 and 2024 was 18%. |
| Is Medeze Group profitable? | Yes, Medeze Group is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
